Phenprocoumon

Phenprocoumon is an anticogulant functioning as Vit K antagonist.It is derivative of Coumarin.

Brands
Adult Dose
Neonatal
Paedriatic
Characteristics
. The Molecular Weight of Phenprocoumon is 280.32.
Contraindications
Phenprocoumon is contraindicated in conditions like Blood dyscrasias,Pregnancy,Renal impairment.
Effects
The severe or irreversible adverse effects of Phenprocoumon, which give rise to further complications include Hemorrhage, Skin necrosis, Hematoma.The signs and symptoms that are produced after the acute overdosage of Phenprocoumon include Melena, Hematuria, Jaundice, Bleeding problems, Pancreatitis.The symptomatic adverse reactions produced by Phenprocoumon are more or less tolerable and if they become severe, they can be treated symptomatically, these include Alopecia, Diarrhea, Nausea and vomiting.
Indications
Phenprocoumon is primarily indicated in conditions like Prophylaxis of recurrent haemorrhage, Thrombo-embolic complications, Venous thromboembolic disease, and can also be given in adjunctive therapy as an alternative drug of choice in Ischemic stroke prophylaxis.
Interactions
Phenprocoumon is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCholestyramineDue to enterohepatic cycling and the long half-life of phenprocoumon, an interaction between these two drugs could not be avoided. We therefore recommend that cholestyramine not be administered to patients treated with drugs undergoing enterohepatic cycling, such as oral anticoagulants.Metformin (HCl)Metformin increases elimination of phenprocoumon.Reviparin SodiumPhenprocoumon may potentiate the action of Reviparin. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Phenprocoumon should not be given to patients who are hemmorhagic. Dose alteration should be guided by regular monitoring of oral anticogulant therapy.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.